Pharma BD Deal Intelligence
AbbVie's decade-plus bet on Calico's aging science ended in collapse: after a 2021 extension added $500 million more, the 11-year alliance wound down in November 2025 and AbbVie laid off roughly 100 chemists once fosigotifator failed the HEALEY ALS Platform Trial.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie and Calico will each contribute another $500 million to extend their long-running aging research collaboration, the companies said Tuesday. The…
AbbVie and Calico Life Sciences said on Tuesday they would extend their seven-year-old research collaboration with each company contributing an additional…
The second extension of the Calico-AbbVie aging research collaboration brings cumulative committed capital to roughly $2.5 billion, making it one of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
AbbVie and Calico Life Sciences announced the second extension of their 2014 aging and age-related disease collaboration on July 27, 2021, with each partner committing an additional ~$500M (~$1B incremental; ~$3.5B cumulative alliance value). The pipeline spanned 20+ early-stage programs in immuno-oncology and neurodegeneration, with three in clinical development at the time, anchored by the PTPN2/N1 inhibitor osunprotafib (ABBV-CLS-484) in oncology and the eIF2B activator fosigotifator (ABBV-CLS-7262) in neurodegeneration. OUTCOME: The collaboration ended in November 2025 (reported Nov 12-13). AbbVie wound down the 11-year alliance and laid off ~100 chemists after fosigotifator failed to significantly slow disease progression in the HEALEY ALS Platform Trial (reported Jan 2025) and AbbVie pivoted away from small-molecule discovery toward biologics and genetic medicines. Over its life the alliance produced limited clinical success; the anti-PAPP-A antibody ABBV-CLS-628 (ADPKD; FDA fast-track Oct 2025) and the osunprotafib oncology Phase 1 (NCT04777994) continued under AbbVie at the time of the wind-down.
6.5M US cases/yr · $150.0B Combined global oncology + neurodegeneration market 2021 · ~$1.0B Total committed capital across both partners (incremental ~$500M each)
The AbbVie-Calico collaboration targets the broad biology of aging and age-related diseases, with two clinical anchors: immuno-oncology (PTPN2 inhibition and adjacent targets) and neurodegeneration (Alzheimer's disease and ALS-adjacent programs). Alzheimer's disease alone affects approximately 6.5 million U.S. adults and is projected to reach 13 million by 2050. ALS affects about 30,000 U.S. patients with an annual incidence near 5,000. Solid tumor immuno-oncology represents a $40B+ U.S. addressable market dominated by checkpoint inhibitor backbones (Keytruda, Opdivo). Calico's strategic differentiation is its multi-omic aging biology platform, founded by Google/Alphabet in 2013 and led by former Genentech CEO Art Levinson and CSO David Botstein. The collaboration is one of the longest-running discovery alliances in pharma — the original 2014 deal preceded the current extension by seven years and has produced 20+ early-stage programs with three in clinical development by 2021. Therapeutic pricing across the relevant indications spans $5K-25K per month for novel oncology agents and $1K-5K per month for branded neurodegeneration therapies, although disease-modifying products in Alzheimer's command premium WAC near $26,500 per year (Leqembi).
The aging biology and age-related disease landscape spans multiple modalities. In immuno-oncology, PTPN2/PTP1B inhibition is a competitive niche led by Calico's lead clinical asset alongside Calico Pharma/Roche partnership programs and academic spinouts. Senolytic and senescence-targeted therapeutics include Unity Biotechnology's UBX1325 (FOXO4-p53 disruptor in DME/AMD) and Resilience Bio. Neurodegeneration programs across the pipeline include lecanemab (anti-amyloid mAb, Eisai/Biogen, approved Jan 2023), donanemab (anti-amyloid mAb, Lilly, approved July 2024), aducanumab (Aduhelm, Biogen, withdrawn 2024), and tofersen (anti-SOD1 ASO, Biogen, approved 2023 for SOD1-ALS). Anti-tau monoclonal antibodies include semorinemab (Genentech/AC Immune) and zagotenemab (Lilly, discontinued). The Calico-AbbVie aging biology approach is differentiated by upstream target discovery in basic biology of cellular senescence rather than amyloid/tau-axis therapeutics, positioning the collaboration as a long-horizon platform play complementary to AbbVie's existing immunology and oncology portfolios. Other aging-platform competitors include Altos Labs (cellular reprogramming, Jeff Bezos-backed) and Retro Biosciences (OpenAI's Sam Altman-backed).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Calico Life Sciences LLC (this deal) | 2021 | $1.0B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2021 deals · AbbVie Inc. deals · Neurology deals